These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 24709975)

  • 1. Implementing precision medicine initiatives in the clinic: a new paradigm in drug development.
    Hollebecque A; Massard C; Soria JC
    Curr Opin Oncol; 2014 May; 26(3):340-6. PubMed ID: 24709975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of tumor sequencing on the use of anticancer drugs.
    Thomas F; Desmedt C; Aftimos P; Awada A
    Curr Opin Oncol; 2014 May; 26(3):347-56. PubMed ID: 24709974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What have we learned from exceptional tumour responses?: Review and perspectives.
    Mehra N; Lorente D; de Bono JS
    Curr Opin Oncol; 2015 May; 27(3):267-75. PubMed ID: 25811347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Personalized oncology: genomic screening in phase 1.
    Tuxen IV; Jønson L; Santoni-Rugiu E; Hasselby JP; Nielsen FC; Lassen U
    APMIS; 2014 Aug; 122(8):723-33. PubMed ID: 25046202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.
    Workman P
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S45-56. PubMed ID: 12819933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Possibilities and limitations of stratified medicine based on biomarkers and targeted therapies in oncology].
    Ludwig WD
    Z Evid Fortbild Qual Gesundhwes; 2012; 106(1):11-22. PubMed ID: 22325103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Somatic alterations as the basis for resistance to targeted therapies.
    Blair BG; Bardelli A; Park BH
    J Pathol; 2014 Jan; 232(2):244-54. PubMed ID: 24114654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of anti-cancer drugs.
    Arrondeau J; Gan HK; Razak AR; Paoletti X; Le Tourneau C
    Discov Med; 2010 Oct; 10(53):355-62. PubMed ID: 21034677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?
    Carden CP; Sarker D; Postel-Vinay S; Yap TA; Attard G; Banerji U; Garrett MD; Thomas GV; Workman P; Kaye SB; de Bono JS
    Drug Discov Today; 2010 Feb; 15(3-4):88-97. PubMed ID: 19961955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomarker-driven patient selection for early clinical trials.
    Dienstmann R; Rodon J; Tabernero J
    Curr Opin Oncol; 2013 May; 25(3):305-12. PubMed ID: 23493192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Personalized oncology: recent advances and future challenges.
    Kalia M
    Metabolism; 2013 Jan; 62 Suppl 1():S11-4. PubMed ID: 22999010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted therapy in cancer.
    Tsimberidou AM
    Cancer Chemother Pharmacol; 2015 Dec; 76(6):1113-32. PubMed ID: 26391154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Personalizing oncology: perspectives and prospects.
    Mendelsohn J
    J Clin Oncol; 2013 May; 31(15):1904-11. PubMed ID: 23589547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The genetic complexity of common cancers and the promise of personalized medicine: is there any hope?
    Arnedos M; Vielh P; Soria JC; Andre F
    J Pathol; 2014 Jan; 232(2):274-82. PubMed ID: 24114621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parallel anticancer drug development and molecular stratification to qualify predictive biomarkers: dealing with obstacles hindering progress.
    Garcia VM; Cassier PA; de Bono J
    Cancer Discov; 2011 Aug; 1(3):207-12. PubMed ID: 22586572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The development and potential clinical utility of biomarkers for HDAC inhibitors.
    Shi B; Xu W
    Drug Discov Ther; 2013 Aug; 7(4):129-36. PubMed ID: 24071574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimising translational oncology in clinical practice: strategies to accelerate progress in drug development.
    Stahel R; Bogaerts J; Ciardiello F; de Ruysscher D; Dubsky P; Ducreux M; Finn S; Laurent-Puig P; Peters S; Piccart M; Smit E; Sotiriou C; Tejpar S; Van Cutsem E; Tabernero J
    Cancer Treat Rev; 2015 Feb; 41(2):129-35. PubMed ID: 25533737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Defining precision: The precision medicine initiative trials NCI-MPACT and NCI-MATCH.
    Coyne GO; Takebe N; Chen AP
    Curr Probl Cancer; 2017; 41(3):182-193. PubMed ID: 28372823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The possibility of clinical sequencing in the management of cancer.
    Kou T; Kanai M; Matsumoto S; Okuno Y; Muto M
    Jpn J Clin Oncol; 2016 May; 46(5):399-406. PubMed ID: 26917600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular targets and targeted therapeutics in endometrial cancer.
    Weigelt B; Banerjee S
    Curr Opin Oncol; 2012 Sep; 24(5):554-63. PubMed ID: 22581357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.